ALCON LABS INC — Patent Portfolio
1 drug with active patents · 5 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict The ALCON LABS INC portfolio is relatively weak with a high average vulnerability score of 62, and the company faces a significant cliff year in 2031 with 1 drug losing exclusivity.
Portfolio overview The ALCON LABS INC portfolio consists of a total of 5 drugs, with 1 of them having patents. The company has a total of 5 US patents, all of which are active. The average vulnerability score of the portfolio is 62, indicating a relatively high level of vulnerability. There are no ironclad patents and no vulnerable patents in the portfolio. Additionally, there are no biologics in the portfolio.
Cliff calendar The company faces a significant cliff year in 2031, with 1 drug losing exclusivity. Specifically, Tryptyr will lose exclusivity in 2031. This is the only year in the next 5 years where a drug will lose exclusivity.
Most exposed drugs The top drug facing near-term loss of exclusivity is Tryptyr, with an earliest active patent expiry date of 2031-09-08 and an average vulnerability score of 62. Unfortunately, the annual revenue for Tryptyr is not available. This drug is the only one in the portfolio with a patent count of 5.
Biologic exclusivity There are no biologics in the portfolio, which means there are no biologics with BPCIA 12-year reference product exclusivity.
Strategic implications The company faces a total revenue at risk of $0 in the next 5 years. Given the weak portfolio and the significant cliff year in 2031, the company may consider lifecycle moves such as subQ switches, label extensions, or combination filings to mitigate the impact of the loss of exclusivity for Tryptyr.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Tryptyr (ACOLTREMON)
Cliff 2031 · 5y-
US10028920
Vuln 64
2031-09-08
This patent protects methods for treating ocular irritation involving tearing by administering modulators of the TRPM8 receptor.
-
US9433679
Vuln 64
2031-09-08
This patent protects the use of TRMP8 receptor agonist and antagonist ligands for treating dry eye and epiphora.
-
US9095609
Vuln 64
2031-09-08
This patent protects ophthalmic compositions containing WS-12 and methods for treating dry eye and epiphora.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 5 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track ALCON LABS INC's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export